Barrett, AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J Haematol. 2008;142(6):877–88.CrossRefGoogle ScholarPubMed

Gale, RP, Horowitz, MM, Ash, RC, Champlin, RE, Goldman, JM, Rimm, AA, Ringdén, O, Stone, JA, Bortin, MM.Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 1994;120(8):646–52.CrossRefGoogle ScholarPubMed

Barrett, AJ, Ringdén, O, Zhang, MJ, Bashey, A, Cahn, JY, Cairo, MS, Gale, RP, Gratwohl, A, Locatelli, F, Martino, R, Schultz, KR, Tiberghien, P. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000;95(11):3323–7.Google ScholarPubMed

Ringdén, O, Pavletic, SZ, Anasetti, C, Barrett, AJ, Wang, T, Wang, D, Antin, JH, Di Bartolomeo, P, Bolwell, BJ, Bredeson, C, Cairo, MS, Gale, RP, Gupta, V, Hahn, T, Hale, GA, Halter, J, Jagasia, M, Litzow, MR, Locatelli, F, Marks, DI, McCarthy, PL, Cowan, MJ, Petersdorf, EW, Russell, JA, Schiller, GJ, Schouten, H, Spellman, S.The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009;113(13):3110–8.CrossRefGoogle Scholar

Vago, L, Toffalori, C, Ciceri, F, Fleischhauer, K. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin Oncol. 2012;39(6):707–15.CrossRefGoogle ScholarPubMed

Weisdorf, D, Which donor or graft source should you choose for the strongest GVL? Is there really any difference. Best Pract Res Clin Haematol 2013; 26: 293–6.CrossRefGoogle ScholarPubMed

Pegram, HJ, Ritchie, DS, Smyth, MJ, Wiernik, A, Prince, HM, Darcy, PK, Kershaw, MH. Alloreactive natural killer cells in hematopoietic stem cell transplantation. Leuk Res. 2011;35(1):14–21.CrossRefGoogle ScholarPubMed

Moretta, L, Locatelli, F, Pende, D, Marcenaro, E, Mingari, MC, Moretta, A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117(3):764–71.CrossRefGoogle ScholarPubMed

Davies, JO, Stringaris, K, Barrett, JA, Rezvani, K. Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy. 2014;May 20. [Epub ahead of print]CrossRefGoogle Scholar

Reshef, R, Hexner, EO, Frey, NV, Stadtmauer, EA, Luger, SM, Mangan, JK, Gill, SI, Vassilev, P, Lafferty, KA, Smith, J, Van Deerlin, VM, Mick, R4, Porter, DL. Early donor chimerism levels predict relapse and survival after allogeneic stem-cell transplantation with reduced intensity conditioning. Biol Blood Marrow Transplant. 2014; Jul 9. [Epub ahead of print]CrossRefGoogle Scholar

Reisner, Y, Gur, H, Reich-Zeliger, S, Martelli, MF, Bachar-Lustig, E. Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells. Ann N Y Acad Sci. 2005;1044:70–83.CrossRefGoogle ScholarPubMed

Singh, AK, Savani, BN, Albert, PS, Barrett, AJ. Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation.Biol Blood Marrow Transplant. 2007;13(3):339–44.CrossRefGoogle ScholarPubMed

Ringdén, O, Barrett, AJ, Zhang, MJ, Loberiza, FR, Bolwell, BJ, Cairo, MS, Gale, RP, Hale, GA, Litzow, MR, Martino, R, Russell, JA, Tiberghien, P, Urbano-Ispizua, A, Horowitz, MM. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol. 2003;121(6):874–85.CrossRefGoogle ScholarPubMed

Chang, YJ, Weng, CL, Sun, LX, Zhao, YT. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Ann Hematol. 2012;91(3):427–37.CrossRefGoogle ScholarPubMed

Norkin, M, Uberti, JP, Schiffer, CA. Very late recurrences of leukemia: why does leukemia awake after many years of dormancy? Leuk Res. 2011;35(2):139–44.CrossRefGoogle ScholarPubMed

Bacigalupo, A, Vitale, V, Corvo, R, Barra, S, Lamparelli, T, Gualandi, F, Mordini, N, Berisso, G, Bregante, S, Raiola, AM, Van Lint, MT, Frassoni, F. The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br J Haematol. 2000;108:99–104.CrossRefGoogle ScholarPubMed

Locatelli, F, Zecca, M, Rondelli, R, Bonetti, F, Dini, G, Prete, A, Messina, C, Uderzo, C, Ripaldi, M, Porta, F, Giorgiani, G, Giraldi, E, Pession, A. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood. 2000;95:1572–9.CrossRefGoogle ScholarPubMed

Pulsipher, MA, Langholz, B, Wall, DA, Schultz, KR, Bunin, N, Carroll, WL, Raetz, E, Gardner, S, Gastier-Foster, JM, Howrie, D, Goyal, RK, Douglas, JG, Borowitz, M, Barnes, Y, Teachey, DT, Taylor, C, Grupp, SA. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial. Blood. 2014;123(13):2017–25.CrossRefGoogle ScholarPubMed

Khouri, IF, Lee, MS, Saliba, RM, Andersson, B, Anderlini, P, Couriel, D, Hosing, C, Giralt, S, Korbling, M, McMannis, J, Keating, MJ, Champlin, RE. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32(1):28–35.CrossRefGoogle ScholarPubMed

Champlin, RE, Passweg, JR, Zhang, MJ, Rowlings, PA, Pelz, CJ, Atkinson, KA, Barrett, AJ, Cahn, JY, Drobyski, WR, Gale, RP, Goldman, JM, Gratwohl, A, Gordon-Smith, EC, Henslee-Downey, PJ, Herzig, RH, Klein, JP, Marmont, AM, O’Reilly, RJ, Ringdén, O, Slavin, S, Sobocinski, KA, Speck, B, Weiner, RS, Horowitz, MM.T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000;95(12):3996–4003.Google ScholarPubMed

Sheng, Z, Ma, H, Pang, W, Niu, S, Xu, J. In vivo T-cell depletion with antithymocyte globulins improves overall survival after myeloablative allogeneic stem cell transplantation in patients with hematologic disorders. Acta Haematol. 2013;129(3):146–53. doi: 10.1159/000343604. Epub 2012 Nov 30.CrossRefGoogle ScholarPubMed

Devine, SM, Carter, S, Soiffer, RJ, Pasquini, MC, Hari, PM, Stein, A, Lazarus, HM, Linker, C, Stadtmauer, EA, Alyea, EP, Keever-Taylor, CA, O'Reilly, RJ. Low-risk of chronic graft versus host disease and relapse associated with T-cell depleted peripheral blood stem cell transplantation for acute myeloid leukemia in first remission: results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303. Biol Blood Marrow Transplant. 2011;17:1343–1351.CrossRefGoogle Scholar

Bayraktar, UD, de Lima, M, Saliba, RM, Maloy, M, Castro-Malaspina, HR, Chen, J, Rondon, G, Chiattone, A, Jakubowski, AA, Boulad, F, Kernan, NA, O’Reilly, RJ, Champlin, RE, Giralt, S, Andersson, BS, Papadopoulos, EB.Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013;19(6):898–903.CrossRefGoogle ScholarPubMed

Aversa, F, Martelli, MF, Velardi, A. Haploidentical hematopoietic stem cell transplantation with a megadose T-cell-depleted graft: harnessing natural and adaptive immunity. Semin Oncol. 2012;39(6):643–52.CrossRefGoogle ScholarPubMed

Bleakley, M, Heimfeld, S, Jones, LA, Turtle, C, Krause, D, Riddell, SR, Shlomchik, W. Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant. 2014;20(5):705–16.CrossRefGoogle ScholarPubMed

Mielke, S, Solomon, SR, Barrett, AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy. 2005;7(2):109–15.CrossRefGoogle ScholarPubMed

Bastien, JP, Roy, J, Roy, DC.Donor selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Semin Oncol. 2012;39(6):674–82.CrossRefGoogle ScholarPubMed

Amrolia, PJ, Muccioli-Casadei, G, Huls, H, Adams, S, Durett, A, Gee, A, Yvon, E, Weiss, H, Cobbold, M, Gaspar, HB, Rooney, C, Kuehnle, I, Ghetie, V, Schindler, J, Krance, R, Heslop, HE, Veys, P, Vitetta, E, Brenner, MK. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006;108(6):1797–808.CrossRefGoogle ScholarPubMed

Fuchs, EJ. Human leukocyte antigen-haploidentical stem cell transplantation using T-cell-replete bone marrow grafts. Curr Opin Hematol. 2012;19:440–7.CrossRefGoogle ScholarPubMed

Kanakry, CG, Ganguly, S, Zahurak, M, Bolaños-Meade, J, Thoburn, C, Perkins, B, Fuchs, EJ, Jones, RJ, Hess, AD, Luznik, L. Aldehyde dehydrogenase expression drives human regulatory T cell resistance toposttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157.CrossRefGoogle ScholarPubMed

Baron, F, Beguin, Y. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:351–9.CrossRefGoogle ScholarPubMed

Chang, YJ, Huang, XJ.Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood Rev. 2013;27:55–62.CrossRefGoogle Scholar

Kolb, HJ, Rank, A, Chen, X, Woiciechowsky, A, Roskrow, M, Schmid, C, Tischer, J, Ledderose, G.In-vivo generation of leukaemia-derived dendritic cells. Best Pract Res Clin Haematol. 2004;17:439–51.CrossRefGoogle ScholarPubMed

Martino, M, Fedele, R, Moscato, T, Ronco, F.Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents. Curr Cancer Drug Targets. 2013;13:661–9.CrossRefGoogle ScholarPubMed

Joks, M, Jurczyszyn, A, Machaczka, M, Skotnicki, AB, Komarnicki, M. The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. Eur J Haematol. 2015;94(2):109–14.CrossRefGoogle ScholarPubMed

Neelapu, SS, Munshi, NC, Jagannath, S, Watson, TM, Pennington, R, Reynolds, C, Barlogie, B, Kwak, LW.Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant. 2005;36:315–23.CrossRefGoogle ScholarPubMed

Weng, J, Cha, SC, Matsueda, S, Alatrash, G, Popescu, MS, Yi, Q, Molldrem, JJ, Wang, M, Neelapu, SS, Kwak, LW. Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes. Clin Cancer Res. 2011;17(18):5945–52.CrossRefGoogle ScholarPubMed

Rezvani, K, Barrett, AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol. 2008;21:437–53.CrossRefGoogle ScholarPubMed

Falkenburg, JH, Willemze, R.Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract Res Clin Haematol. 2004;17:415–25.CrossRefGoogle ScholarPubMed

Riddell, SR, Bleakley, M, Nishida, T, Berger, C, Warren, EH. Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant. 2006;12 (Suppl 1):9–12CrossRefGoogle ScholarPubMed

Bleakley, M, Otterud, BE, Richardt, JL, Mollerup, AD, Hudecek, M, Nishida, T, Chaney, CN, Warren, EH, Leppert, MF, Riddell, SR. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood. 2010;115(23):4923–33.CrossRefGoogle ScholarPubMed

Warren, EH, Fujii, N, Akatsuka, Y, Chaney, CN, Mito, JK, Loeb, KR, Gooley, TA, Brown, ML, Koo, KK, Rosinski, KV, Ogawa, S, Matsubara, A, Appelbaum, FR, Riddell, SR. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood. 2010;115(19):3869–78.CrossRefGoogle Scholar

Nagai, K, Ochi, T, Fujiwara, H, An, J, Shirakata, T, Mineno, J, Kuzushima, K, Shiku, H, Melenhorst, JJ, Gostick, E, Price, DA, Ishii, E, Yasukawa, M. Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity. Blood. 2012;119:368–76.CrossRefGoogle ScholarPubMed

Linette, GP, Stadtmauer, EA, Maus, MV, Rapoport, AP, Levine, BL, Emery, L, Litzky, L, Bagg, A, Carreno, BM, Cimino, PJ, Binder-Scholl, GK, Smethurst, DP, Gerry, AB, Pumphrey, NJ, Bennett, AD, Brewer, JE, Dukes, J, Harper, J, Tayton-Martin, HK, Jakobsen, BK, Hassan, NJ, Kalos, M, June, CH. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–71.CrossRefGoogle ScholarPubMed

Weber, G, Gerdemann, U, Caruana, I, Savoldo, B, Hensel, NF, Rabin, KR, Shpall, EJ, Melenhorst, JJ, Leen, AM, Barrett, AJ, Bollard, CM. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013;27:1538–47.CrossRefGoogle ScholarPubMed

Weber, G, Caruana, I, Rouce, RH, Barrett, AJ, Gerdemann, U, Leen, AM, Rabin, KR, Bollard, CM.Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia–implications for immunotherapy. Clin Cancer Res. 2013;19:5079–91.CrossRefGoogle ScholarPubMed

Duong, CP, Yong, CS, Kershaw, MH, Slaney, CY, Darcy, PK. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.Mol Immunol. 2015;67(2 Pt A):46–57.CrossRefGoogle ScholarPubMed

Hoffman, LM, Gore, L. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE(®) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front Oncol. 2014; 4:63.CrossRefGoogle ScholarPubMed

Oliveira, G, Greco, R, Lupo-Stanghellini, MT, Vago, L, Bonini, C. Use of TK-cells in haploidentical hematopoietic stem cell transplantation. Curr Opin Hematol. 2012;19:427–33.CrossRefGoogle ScholarPubMed

Tey, SK, Dotti, G, Rooney, CM, Heslop, HE, Brenner, MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:913–24.CrossRefGoogle ScholarPubMed

Karadimitris, A, Chaidos, A. The role of invariant NKT cells in allogeneic hematopoietic stem cell transplantation. Crit Rev Immunol. 2012;32:157–71.CrossRefGoogle ScholarPubMed

Locatelli, F, Merli, P, Rutella, S. At the bedside: innate immunity as an immunotherapy tool for hematological malignancies. J Leuk Biol. 2013;94:1141–57.CrossRefGoogle ScholarPubMed